SCHEMBL3518484

SCHEMBL3518484

COc1cccc(-c2cnc3c(C(=O)NCC(=O)O)c(O)ccc3n2)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 3/20 0.47
ADORA3 P0DMS8 2/20 0.43
ADORA2A P29274 2/20 0.43
ADORA2B P29275 2/20 0.43
FTO Q9C0B1 3/20 0.40
KDM5B Q9UGL1 2/20 0.40
KDM2A Q9Y2K7 2/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
EGLN1 Q9GZT9 5/20 0.39
KDM6B O15054 2/20 0.39
KDM4C Q9H3R0 1/20 0.38
KDM3A Q9Y4C1 1/20 0.38
ATR Q13535 1/20 0.37
MAOB P27338 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520489 0.91 EGLN3 (0.52) EGLN3ADORA3FTOKDM5BKDM2A
SCHEMBL3518292 0.83 EGLN3 (0.49) EGLN3FTOKDM5BKDM2AHSD17B10
SCHEMBL3520841 0.83 EGLN3 (0.47) EGLN3ADORA3KDM4EHPGDEGLN1
SCHEMBL3518299 0.83 EGLN3 (0.49) EGLN3FTOKDM5BKDM2AALDH1A1
SCHEMBL3757200 0.83 EGLN3 (0.57) EGLN3FTOKDM5BKDM2AEGLN1
SCHEMBL3520878 0.81 EGLN3 (0.51) EGLN3KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3519009 0.81 EGLN3 (0.50) EGLN3FTOKDM5BKDM2AEGLN1
SCHEMBL3519422 0.81 EGLN3 (0.53) EGLN3FTOKDM5BKDM2AEGLN1
SCHEMBL3518710 0.80 EGLN3 (0.54) EGLN3FTOKDM5BKDM2AEGLN1
SCHEMBL3518109 0.80 EGLN3 (0.55) EGLN3KDM4EALDH1A1HPGDEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885ADORA3 3353/4885ADORA2A 3714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.